J Rheum Dis 2015; 22(3): 180-185
Published online June 30, 2015
© Korean College of Rheumatology
임은수1ㆍ김영건1ㆍ최원선1ㆍ정유석2ㆍ한재호3ㆍ배창범1ㆍ정주양1ㆍ김현아1ㆍ서창희1
아주대학교 의과대학 1류마티스내과학교실, 2진단검사의학교실, 3병리학교실
Correspondence to : Chang-Hee Suh
Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder characterized by fever, pancytopenia, hyperferritinemia, and phagocytosis of hematopoietic cells in bone marrow, liver, or lymph nodes. HLH can occur during the course of systemic lupus erythematosus (SLE), but can also be a presenting manifestation. Because development of pancytopenia occurs in less than 10 percent of SLE cases, investigation for HLH is necessary when otherwise unexplained pancytopenia persists despite adequate treatment. We experienced three cases of secondary HLH associated with SLE. Among the three patients, two patients devel-oped HLH during the clinical course of SLE. The other patient who presented with pancytopenia was first diagnosed with HLH, and later with SLE. In her case, HLH turned out to be a presenting manifestation of SLE. We report on three successfully treated cases, and discuss the prevalence, characteristics, treatments, and prognosis of secondary HLH associated with SLE. (J Rheum Dis 2015;22:180-185)
Keywords Hemophagocytic lymphohistiocytosis, Systemic lupus erythematosus, Pancytopenia
J Rheum Dis 2015; 22(3): 180-185
Published online June 30, 2015
Copyright © Korean College of Rheumatology.
임은수1ㆍ김영건1ㆍ최원선1ㆍ정유석2ㆍ한재호3ㆍ배창범1ㆍ정주양1ㆍ김현아1ㆍ서창희1
아주대학교 의과대학 1류마티스내과학교실, 2진단검사의학교실, 3병리학교실
Eunsoo Lim1, Young-Geon Kim1, Won-Sun Choi1, Yu-Soek Jung2, Jae-Ho Han3, Chang-Bum Bae1, Ju-Yang Jung1, Hyoun-Ah Kim1, Chang-Hee Suh1
Departments of 1Rheumatology, 2Laboratory Medicine, and 3Pathology, Ajou University School of Medicine, Suwon, Korea
Correspondence to:Chang-Hee Suh
Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder characterized by fever, pancytopenia, hyperferritinemia, and phagocytosis of hematopoietic cells in bone marrow, liver, or lymph nodes. HLH can occur during the course of systemic lupus erythematosus (SLE), but can also be a presenting manifestation. Because development of pancytopenia occurs in less than 10 percent of SLE cases, investigation for HLH is necessary when otherwise unexplained pancytopenia persists despite adequate treatment. We experienced three cases of secondary HLH associated with SLE. Among the three patients, two patients devel-oped HLH during the clinical course of SLE. The other patient who presented with pancytopenia was first diagnosed with HLH, and later with SLE. In her case, HLH turned out to be a presenting manifestation of SLE. We report on three successfully treated cases, and discuss the prevalence, characteristics, treatments, and prognosis of secondary HLH associated with SLE. (J Rheum Dis 2015;22:180-185)
Keywords: Hemophagocytic lymphohistiocytosis, Systemic lupus erythematosus, Pancytopenia
So-Young Bang, M.D., Ph.D., Seung Cheol Shim, M.D., Ph.D.
J Rheum Dis 2024; 31(4): 200-211Alhanouf Adnan Alsharif, M.B.B.S., Abdulaziz Marzouq Almutairi, M.D., Emtenan Badar Basahl, M.B.B.S., Abdulaziz Abdulllah Alshathri, M.D., Jameela Abdulaziz Kari, M.D., Mohammed Ahmad Shalaby, M.D., Mohammed Ahmad Nashawi, M.D.
J Rheum Dis -0001; ():Hae Ryung Kim, M.D., Seon Hee Lim, M.D., Ji Soo Park, M.D., Dong In Suh, M.D., Ph.D., Seungbok Lee, M.D., Soo Yeon Kim, M.D., Jong Hee Chae, M.D., Ph.D., Seong Heon Kim, M.D.
J Rheum Dis 2024; 31(3): 182-187